Marex Group Croissance future
Future contrôle des critères 2/6
Le chiffre d'affaires de Marex Group devrait diminuer de 7.3% par an tandis que ses bénéfices annuels devraient croître de 14.9% par an. Le BPA devrait croître de de 8.2% par an. Le rendement des capitaux propres devrait être 21.2% dans 3 ans.
Informations clés
14.9%
Taux de croissance des bénéfices
8.21%
Taux de croissance du BPA
| Capital Markets croissance des bénéfices | 11.5% |
| Taux de croissance des recettes | -7.3% |
| Rendement futur des capitaux propres | 21.22% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 06 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour de l'analyse • May 07
MRX: Higher Margins And Q1 2026 Outlook Will Support Measured Upside
Analysts have lifted Marex Group's price target from $50.29 to $55.00 as they now factor in a higher profit margin of about 20.9% and a lower future P/E of roughly 9.7, despite softer revenue growth assumptions and a slightly higher discount rate. What's in the News Marex Group issued earnings guidance for the first quarter ended March 31, 2026, with expected revenues in a range of $667 million to $697 million, compared with Q1 2025 revenues of $467 million (Key Developments).
Mise à jour de l'analyse • Apr 22
MRX: Higher Fair Value And Lower Future P/E Will Support Upside
Analysts have lifted their fair value estimate for Marex Group from $61.00 to $66.00, citing updated assumptions for modest positive revenue growth, a slightly higher profit margin, and a lower future P/E of 11.40 compared with the prior 13.35. What's in the News Marex Group issued earnings guidance for the quarter ending March 31, 2026, with expected revenues in a range of $667 million to $697 million, compared with Q1 2025 revenues of $467 million (Key Developments).
Mise à jour de l'analyse • Apr 07
MRX: Rich Earnings Multiple Will Face Test From Softer Revenue Outlook
Analysts have inched their price targets for Marex Group higher by a few dollars into the mid $40s, reflecting updated views on revenue trends, margins, and a lower forward P/E assumption in recent TD Cowen, Piper Sandler, and Barclays research. Analyst Commentary Recent research reflects a mixed tone, with some optimism on Marex Group's revenue and margin outlook, alongside more cautious views on where the shares should trade relative to sector peers.Mise à jour de l'analyse • Mar 24
MRX: Volatility And Trading Volumes Will Test Fairly Priced Shares
Analysts have lifted their average price target on Marex Group by mid single digits. Recent moves include $7 and $5 increases, citing updated assumptions for revenue trends, profit margins, and a lower implied future P/E multiple despite a slightly higher discount rate.Mise à jour de l'analyse • Mar 09
MRX: Higher Trading Volumes And Supportive P/E Will Drive Future Upside
Analysts have lifted their average price target on Marex Group to $61, citing updated views on revenue trajectory, profit margins, and a modestly higher future P/E multiple informed by recent Street research revisions from TD Cowen, Piper Sandler, and Barclays. Analyst Commentary Bullish analysts are leaning into Marex Group's execution by lifting their individual price targets, which helps explain the higher Street average.Mise à jour de l'analyse • Feb 23
MRX: Rising Trading Volumes And Volatility Will Support Earnings Power
Narrative update on Marex Group Analysts have nudged their Marex Group price targets higher by $7 and $5 in recent updates, while one cut a target by $1 to $49. These changes reflect adjusted views on volumes, volatility, and earnings potential rather than a change to our $61 fair value estimate.Mise à jour de l'analyse • Feb 07
MRX: Higher Volatility And Volumes Will Support Earnings Power Going Forward
The analyst price target for Marex Group has increased from $56 to $61, with analysts citing updated views on revenue trends, profit margins, and future P/E assumptions reflected in recent research from TD Cowen, Piper Sandler, and Barclays. Analyst Commentary Recent research updates show bullish analysts lifting their fair value estimates for Marex Group, with the latest round of work incorporating refreshed views on revenue trends, margin resilience, and P/E assumptions.Mise à jour de l'analyse • Jan 23
MRX: US Expansion And Higher Trading Volumes Will Support Future Upside
Analysts have raised their price targets on Marex Group, reflecting a revised fair value estimate from $47.71 to $50.29 as they factor in updated expectations around volumes, revenue trends, margins, and future P/E assumptions following recent sector research. Analyst Commentary Recent research updates on Marex Group show a mix of optimism and caution as analysts refresh their models ahead of upcoming results and sector comparisons.Mise à jour de l'analyse • Jan 08
MRX: Rising Trading Activity Will Support Earnings Power Despite Slight Price Trim
Analysts have trimmed their price target on Marex Group to US$49 from US$50, citing refreshed views on sector volumes and volatility while keeping fair value and key valuation inputs broadly unchanged. Analyst Commentary Bullish analysts are treating the lower US$49 price target as a fine tuning rather than a reset, keeping their broader view on Marex Group intact while they refresh assumptions for sector activity.Mise à jour de l'analyse • Dec 23
MRX Will Benefit From Expanding US Structured Products And Margin Resilience
Analysts have trimmed their price target on Marex Group by 4 percent to $56.00, citing slightly higher discount rates and weaker revenue growth expectations, partly offset by improved profit margin forecasts and a more attractive forward earnings multiple. What's in the News Marex Group launched a US structured products business targeting RIAs, broker dealers, and private banks.Mise à jour de l'analyse • Dec 09
MRX: US Expansion Will Drive Future Upside Despite Pending Securities Lawsuits
Narrative Update on Marex Group Price Target Analysts have modestly reduced their averaged price target on Marex Group from approximately $49.00 to about $47.70. This reflects slightly weaker top line growth assumptions, partially offset by expectations for improved profit margins and a marginally lower future price to earnings multiple.Seeking Alpha • Dec 01
Unfortunate Post-IPO Realities Have Set In For Marex Group
Summary Marex Group (MRX) is rated Hold due to slowing earnings growth and recent reliance on non-organic growth. MRX has pursued aggressive acquisitions, improving diversification but raising risks of shareholder dilution and integration challenges. The company maintains strong revenue growth and a conservative dividend payout, but its yield remains below industry averages. Despite its current attractive valuation, future prospects for profit growth and mixed insider activity limit the stock's near-term upside potential. Read the full article on Seeking AlphaMise à jour de l'analyse • Nov 25
MRX: Diversified US Expansion Will Drive Recovery Despite Securities Lawsuit Risk
Analysts have raised their price target for Marex Group from $47.67 to $49.00, citing updated assumptions around profit margins and discount rates, which support a modestly higher valuation. What's in the News Marex Group has launched its structured products business in the United States, led by Scott Kerbel.Mise à jour de l'analyse • Nov 06
MRX: Revenue Outlook Will Support Rebound Despite Ongoing Class Action Lawsuits
Analysts have made a minor upward adjustment to the price target for Marex Group, now set at $47.67. This change is based on slight improvements in the revenue growth outlook and a stable discount rate.Mise à jour de l'analyse • Oct 23
Analysts Lower Marex Group Price Target Amid Accounting Allegations and Revised Profit Outlook
Analysts have slightly lowered their price target for Marex Group from $49.33 to $47.67. This change reflects recent updates to the company’s growth and profitability outlook.Mise à jour de l'analyse • Oct 08
Digitalization And M&A Will Unlock Global Market Potential
Analysts have lowered their price target for Marex Group from $50.89 to $49.33, citing slightly reduced profit margin forecasts and modestly improved revenue growth projections. What's in the News NINGI Research disclosed a short position in Marex Group, alleging the company used opaque off-balance-sheet entities, fictitious transactions, and misleading disclosures to obscure losses and inflate profits (Periodical).Article d'analyse • Aug 06
Here's Why Marex Group (NASDAQ:MRX) Has Caught The Eye Of Investors
NasdaqGS:MRX 1 Year Share Price vs Fair Value Explore Marex Group's Fair Values from the Community and select yours...
Nouvelle analyse • Apr 27
Acquisitions Will Fuel APAC And Middle East Expansion
Strong market share gains and acquisition integration are driving revenue growth and expanding product offerings and geographic reach.Article d'analyse • Apr 10
Further Upside For Marex Group plc (NASDAQ:MRX) Shares Could Introduce Price Risks After 26% Bounce
Marex Group plc ( NASDAQ:MRX ) shareholders have had their patience rewarded with a 26% share price jump in the last...Article d'analyse • Dec 25
Many Still Looking Away From Marex Group plc (NASDAQ:MRX)
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 2,855 | 511 | N/A | N/A | 3 |
| 12/31/2027 | 2,588 | 439 | N/A | N/A | 7 |
| 12/31/2026 | 2,567 | 397 | N/A | N/A | 3 |
| 3/31/2026 | 3,266 | 334 | N/A | N/A | N/A |
| 12/31/2025 | 2,870 | 294 | 648 | 668 | N/A |
| 9/30/2025 | 2,668 | 266 | N/A | N/A | N/A |
| 6/30/2025 | 2,608 | 251 | 1,617 | 1,639 | N/A |
| 3/31/2025 | 2,530 | 234 | N/A | N/A | N/A |
| 12/31/2024 | 2,357 | 205 | 1,144 | 1,164 | N/A |
| 9/30/2024 | 2,142 | 189 | N/A | N/A | N/A |
| 6/30/2024 | 1,883 | 134 | N/A | N/A | N/A |
| 3/31/2024 | 1,849 | 140 | N/A | N/A | N/A |
| 12/31/2023 | 1,882 | 128 | 723 | 735 | N/A |
| 9/30/2023 | 1,092 | 140 | N/A | N/A | N/A |
| 6/30/2023 | 1,818 | 139 | N/A | N/A | N/A |
| 3/31/2023 | 1,570 | 115 | N/A | N/A | N/A |
| 1/1/2023 | 1,010 | 92 | 216 | 226 | N/A |
| 1/1/2022 | 825 | 57 | 464 | 471 | N/A |
| 12/31/2020 | 758 | 44 | -51 | -46 | N/A |
| 12/31/2019 | 549 | 36 | N/A | -23 | N/A |
| 12/31/2018 | 384 | 10 | N/A | 130 | N/A |
| 12/31/2017 | 318 | 18 | N/A | -96 | N/A |
| 12/31/2016 | 328 | 20 | N/A | 30 | N/A |
| 12/31/2015 | 346 | 18 | N/A | 8 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MRX ( 14.9% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de MRX ( 14.9% par an) devraient croître plus lentement que le marché US ( 16.4% par an).
Croissance élevée des bénéfices: Les bénéfices de MRX devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Les revenus de MRX devraient diminuer au cours des 3 prochaines années ( -7.3% par an).
Croissance élevée des revenus: Les revenus de MRX devraient diminuer au cours des 3 prochaines années ( -7.3% par an).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de MRX devrait être élevé dans 3 ans ( 21.2 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/07 19:51 |
| Cours de l'action en fin de journée | 2026/05/07 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Marex Group plc est couverte par 13 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Benjamin Budish | Barclays |
| Christopher Allen | Citigroup Inc |
| Alexander Blostein | Goldman Sachs |